cyrilzakka/clinical-trials huggingface dataset:
Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm

Subclavian steal phenomenon is normally observed in patients with stenosis of subclavian artery proximal to orifice of vertebral artery(V0). However, uremic patients undergoing hemodialysis using vascular access in the arm or forearm may also develop dialysis associated steal syndrome(DASS).For patients with symptomatic subclavian steal phenomenon, the treatment for these two groups is different. The investigators want to see if the investigators can use noninvasive duplex examination instead of invasive conventional angiography to do the differential diagnosis.

Carotid duplex is widely used for diagnosis of subclavian steal syndrome. We have a patient who suffered from acute brain stem stroke after receiving hemodialysis for months. He has DM related uremia and the vascular access is in the forearm. Subclavian steal was found on duplex in the same arm for hemodialysis. We used standard cuff test for diagnosis of subclavian steal by carotid duplex examination. Accidentally, we found the flow of subclavian artery was back to normal when the cuff is on that stops the flow. We want to see if this phenomenon can be used to serve as a differential diagnostic tool for differentiation of subclavian steal caused by stenosis of subclavian artery or due to DASS.

Eligibility Criteria:
Inclusion Criteria:

* patients who revealed subclavian steal in the duplex study

Exclusion Criteria:

* patients who has vascular access in the arm instead of the forearm
Impact of Minimally Invasive and Open Liver Surgery in Different BMI-classes

Despite the worldwide increase of both obesity and use of minimally invasive liver surgery(MILS), evidence regarding the safety and eventual benefits of MILS in obese patients is scarce. The aim of this study is therefore to compare the outcomes of non-obese and obese patients(BMI 18.5-29.9 and BMI≥30, respectively) undergoing MILS and OLS, and to assess trends in MILS use among obese patients. In this retrospective cohort study, patients operated at 20 hospitals in eight countries(2009-2019) will be included and the characteristics and outcomes of non-obese and obese patients will be compared. Thereafter, the outcomes of MILS and OLS were compared in both groups after propensity-score matching(PSM). Changes in the adoption of MILS during the study period will be investigated.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years and older
* Patients that have undergone an elective minimally invasive or open liver resection

Exclusion Criteria:

* Patients that have undergone a hand-assisted or robotic procedure
* Patients with a BMI lower than 18.5
External Cephalic Version (ECV) for Twins With Non-vertex Presenting Twin

In this study, women with a twin pregnancy with the presenting twin in a non-vertex(head) presenting twin undergo an external cephalic version.


Eligibility Criteria:
Inclusion Criteria:

* 18 years old or older multiparous no previous cesarean delivery (CD) a non-vertex presenting twin in a term (37 weeks gestation and onwards) dichorionic diamniotic twin pregnancy

Exclusion Criteria:

* contraindication for a vaginal delivery nulliparous monochorionic diamniotic pregnancy
A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs

This is a randomized double-blind crossover study of the patients with stable heart failure, who are taking a loop diuretic. During the study period, the participants' loop diuretics will be replaced by the equivalent dose of immediate release/extended release torsemide for one week. After a one week period, they will report to the site and will receive a single dose of either immediate release or extended release Torsemide. The sodium excretion will be measured for six hours after dosing and for an additional six hours after a high salt lunch.

The goal of this randomized double-blind crossover study is to assess whether extended release torsemide has a better efficacy than immediate release torsemide to induce renal sodium excretion after a salty lunch in patients with heart failure. The study will address if:

* the amounts of excreted sodium in the urine during the 2- and 6-hours' time period after a morning dose of extended release torsemide is different from the amounts after the immediate release torsemide.
* the amounts of excreted sodium in the urine during the 2- and 6-hours' time period after a salty lunch, which will be consumed approximately 6 hours following a morning dose of extended release torsemide, is different from the amounts after the immediate release torsemide.
* the amount of excreted sodium in the urine during the 24 hours' time period after a salty lunch, which will be consumed approximately 6 hours following a morning dose of extended release torsemide, is different from the amount after the immediate release torsemide.

Eligibility Criteria:
Inclusion Criteria:

* Man or woman over the age of 18 years.
* Willing and able to sign the informed consent.
* A clinical diagnosis of chronic HF that is considered by patient's cardiologist/physician or an experienced clinician to be stable over the one-month period prior to randomization.
* Receiving oral furosemide (or equivalent doses of torsemide or bumetanide) for about 30 days prior to randomization.
* No anticipated changes in HF medications during the study period.
* Premenopausal women of child-bearing potential have a negative pregnancy test prior to beginning of the study and agree to use effective contraceptive methods during the study period

Exclusion Criteria:

* Requirement for a diuretic other than furosemide, bumetanide or torsemide except for spironolactone, eplerenone, finerenone, or SGLT2 inhibitors, at randomization and during the study.
* Myocardial infarction, stroke, transient ischemic attack, acute kidney injury or acute HF requiring admission to hospital within the last 30 days prior to randomization.
* Severe / symptomatic lung disease or respiratory symptoms distinct from HF.
* Urinary incontinence or inability to empty bladder.
* Uncontrolled diabetes mellitus or uncontrolled hypertension.
* Estimated GFR \< 30 ml/min/1.72m2.
* History of flash pulmonary edema or amyloid cardiomyopathy.
* Female patients who are breastfeeding.
Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections

Purpose of the study:

The overall goal of this study is to better understand patient experience with injectable facial fillers so that the investigators may provide the best results for their patients. To do this, the investigators are administering surveys to approximately 50 patients who have been treated by Dr. Anthony P Sclafani, MD, FACS.

Participation:

Participants will be asked to complete a brief questionnaire regarding their most recent treatment by Dr. Sclafani with a facial injectable filler. All responses will be analyzed anonymously.

Patients previously treated by the PI with dermal fillers will be mailed questionnaires about their experience with the treatment. These questionnaires will be deidentified prior to recording answers on a computer based spreadsheet.

Eligibility Criteria:
Inclusion Criteria:

* Patients treated by Principal Investigator with facial soft tissue filler within the past 2 years willing to complete the research survey.

Exclusion Criteria:

* Any patient not treated by Principal Investigator with facial soft tissue filler within the past 2 years.
Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People (KnoVIB)

The standard recommendation to prevent osteoporosis is to supplement low doses of vitamin D and calcium. Hyperhomocysteinemia has been related to increased risk of osteoporosis.

The current study aimed at investigating if homocysteine-lowering effect (low doses of B-vitamins) will add any measurable beneficial effect on bone markers when added to the standard recommendations for prevention of osteoporosis.

Eligibility Criteria:
Inclusion Criteria:

* age\> 50 years,
* male and female

Exclusion Criteria:

* renal dysfunction,
* recent stroke or coronary event within the last 3 months,
* current cancer,
* antifolate treatment,
* ileum resection,
* existing B vitamins supplementation,
* megaloblastic anemia,
* osteoporotic patients treated with pharmacological doses of vitamin D or antiosteoporotic drugs.

Termination criteria were:

* indication for a high-dose vitamin B supplementation,
* coronary or vascular event,
* or surgical procedures during the study.
StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Autografting is a surgical procedure to transplant healthy skin (donor skin) from another part of the participant's own body (donor site) to the burned part. Autografting is the usual treatment for DPT burns.

It works to close the wound, but can cause other problems:

* Donor sites are painful, can become infected or scarred, or can even become full thickness (FT) wounds themselves
* Treatment problems can require more grafting
* Additional surgery increases the risk of medical problems caused by the treatment

Stratatech is trying to find a safe and effective alternative to autografting to promote the healing of severe burns. The purpose of this study was to evaluate whether StrataGraft treatment eliminates or reduces the need for autografting and promotes wound closure in a pediatric population with thermal burns that contain intact dermal elements and for which autografting is clinically indicated (DPT burns).

Participants were enrolled into one of two age-based cohorts: 2 to \< 12 years and 12 to ≤ 17 years to receive a single application of StrataGraft, in up to 3 non-contiguous DPT burn areas located on the same extremity or plane of the torso.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent provided by the parent(s) or legal guardian(s) and assent from the child when appropriate
* Have enough healthy skin to reserve as donor site(s), in case autografting becomes necessary
* Thermal burns of no more than a total of 30% TBSA
* Study treatment sites that are DPT in depth and which are clinically indicated for excision and autografting, and located on the torso or extremities
* Study treatment area(s) totaling 0.5% to 10% TBSA and may be composed of up to 3 non-contiguous areas located on the same extremity or plane of the torso
* Sufficient healthy skin available and reserved as a donor site in the event that the StrataGraft treatment site requires autografting

Exclusion Criteria:

* Is pregnant or breastfeeding
* Receiving treatment to suppress the immune system and/or systemic corticosteroids (inhaled corticosteroids are permitted)
* A known history of malignancy
* Pre-admission insulin-dependent diabetes
* Concurrent trauma, conditions, and/or personal situations that, in the opinion of the investigator, may compromise the participant's safety or the study objectives
* A burn injury that occurred ≥ 14 days prior to planned StrataGraft application Is expected to survive less than 12 months
* Is participating in another interventional trial, or did within 90 days before enrollment
* A proposed study treatment site that has been previously excised or autografted; located adjacent to an undebrided/unexcised burn area; demonstrates signs and symptoms of wound infection, per judgement of the clinical investigator; lies across joints or is located on the feet (i.e., distal to the malleolus), hands (distal to the wrist), face, neck, buttocks, perineum, or genitalia
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).


Eligibility Criteria:
Inclusion Criteria

* Portion A: Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy or B cell lymphoma, for which no curative therapy is available. Portion A expansion includes patients who have documented disease progression on a checkpoint inhibitor (anti CTLA 4, anti PD1/PD L1 antibodies) per RECIST criteria. Tumor types include metastatic melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NCSLC) and squamous cell carcinoma of the head and neck (SCCHN). Patients in the dose expansion stage are required to provide archival or baseline (obtained during the screening period) tumor biopsies.
* Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which no curative therapy is available. Patients enrolled in the expansion cohort must have archival tissue available, sampled within 6 months of study entry. The Expansion cohort includes patients with FL or DLBCL with relapsed or refractory disease.
* Measurable disease with at least one extranodal tumor mass \>1.0 cm in the greatest transverse diameter (GTD) or in the case of malignant lymph nodes \>1.5 cm in the GTD.
* ECOG performance status of ≤ 1.
* Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥100 x 109/L, hemoglobin \>9.0 g/dL. For Portion B: ANC ≥ 1.0 x 109/L, platelet count ≥ 75 x 109/L, and hemoglobin ≥ 8.0 g/dL. In both cases, patients must be transfusion independent at least 14 days prior to screening.
* Serum creatinine ≤ 2 x ULN or estimated creatinine clearance ≥ 50 ml/min.
* Total serum bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome and AST and ALT ≤ 2.5 x ULN.

Exclusion Criteria

* Patients with known symptomatic brain metastases requiring steroids.
* Prior allogeneic hematopoietic stem cell transplant.
* Immunosuppressive regimens involving systemic corticosteroids within 14 days before the first dose of study treatment.
* Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation therapy within 14 days of the first dose of study drug.
* Autoimmune disorders and other diseases that compromise or impair the immune system.
* Unstable or serious concurrent medical conditions in the previous 6 months.
* Prior therapy with any anti CD137 monoclonal antibody.
Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction

For patients undergoing Anterior Cruciate Ligament reconstruction surgery, the postoperative period can be a painful experience without adequate pain management. Hence the investigators propose a randomized controlled clinical study, investigating prolonged saphenous nerve blocks. Patients will be randomized to receive saphenous nerve blocks with or without dexamethasone, a corticosteroid used to prolong analgesia.

Depending on the randomized treatment assignment, patients may receive one of the following:

1. 13 ml of 0.5% bupivacaine, a local anesthetic (no dexamethasone);
2. 13 ml of 0.5% bupivacaine mixed with 1 mg of dexamethasone;
3. 13 ml of 0.5% bupivacaine mixed with 4 mg of dexamethasone.

Patients will be followed postoperatively. Following admission to the recovery room, data collectors will ask patients to rate their pain on a scale of 0-10 until discharge. Data collectors will also record patient satisfaction, pain medication use and any side effects experienced (i.e. nausea and vomiting). Patients will then be contacted on postoperative days 1, 2 and 14 and asked questions about their general well-being.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing ambulatory surgery for anterior cruciate ligament (ACL) reconstruction with a patella tendon autograft.
* ASA I-III \[American Society of Anesthesiologists (ASA) Physical Status classification system\]
* BMI \< 35
* Smokers included
* Ages 16-65

Exclusion Criteria:

* Patients on steroids or requiring stress dose steroids
* BMI \> 35
* Patient refusal
* Allergy to study medications,
* NRS scores \> 3 with frequent opioid use (including tramadol) prior to surgery-daily for greater than 3 weeks
* Lower extremity neurological dysfunction
* Diabetic (NIDDM, insulin-dependent and/or oral hypoglycemic dependent)
* Not in included age range (under 16 or over 65 years of age)
* Contraindications to the use of dexamethasone
* Non-English speaking patients. We will be using the Short Form 8 Health Survey, as well as the OR-SDS questionnaire (these are in English; any translations would have to be separately validated).
Investigation of the iStent Inject® Devices in Open-Angle Glaucoma

The aim of this study is to evaluate the safety and intraocular pressure (IOP) lowering effect of two iStent inject devices in combination with cataract surgery in patients with mild-to-moderate open-angle glaucoma.

Patients suffering from open-angle glaucoma who are planning to undergo cataract surgery and are matching the inclusion criteria will be offered to join the study until the desired sample size (50) is reached. Combined cataract-iStent surgery will be performed as per the devices' manufacturers' instructions. Two iStent inject devices will be micro-invasively implanted in the trabecular meshwork of the eye during planned cataract surgery. Six post-operative follow-ups will be carried out over a duration of 12 months, during which various measurements will be made. Performance Outcomes will analyse the proportion of patients with IOP reduction of ≥ 20% vs. baseline mean IOP, at 6 and 12 months. Quality of life outcome will look at the improvement in perceived quality of life as expressed in the NEI VFQ-25 questionnaires from baseline to 3 and 12 months. The rate of adverse events will be recorded.

Eligibility Criteria:
Inclusion Criteria:

* Primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma
* Mild to moderate glaucoma (defined as C/D ratio ≤ 0.8)
* Phakic eye requiring cataract surgery
* Preoperative IOP up to 30 mmHg (medicated or not)
* Patients with side-effects to, or complications from, medications
* Patients who would benefit from a reduction of IOP and/or reduction of medication
* Normal angle anatomy as determined by gonioscopy;
* Absence of peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities that could impair proper placement of iStent inject device
* Able and willing to attend scheduled follow-up exams for 12 months postoperatively
* Able and willing to provide written informed consent on the approved Informed Consent Form

Exclusion Criteria:

* Inclusion of the fellow eye in this study (only one eye per subject)
* Aphakic patients or pseudophakic patients
* Prior stent implantations in the study eye
* Eyes with primary angle closure glaucoma, or any secondary angle closure glaucoma
* Traumatic or uveitic glaucoma; or any glaucoma associated with vascular disorders
* Patients with any type of condition that may cause elevated episcleral venous pressure
* Functionally significant visual field loss, including severe nerve fiber bundle defects such as Bjerrum scotoma
* Prior glaucoma treatment (laser or surgery)
* Any active corneal inflammation, edema, or opacity severe-enough to impair gonioscopy / fundus examination
* Any pathology for which, in the investigator's judgment, the following would be either at risk or contraindicated:

  * stent implantation,
  * compliance to elements of the study protocol.
Alteration of Sweet Taste Perception After Reduction of Sweet Food and Beverage Consumption.

The goal of this clinical trial is to determine whether reducing sugar intake by 50% for 12 weeks can change sweet taste perception in healthy adults and its consequences. The main questions it aims to answer are:

* Does sweet intensity change after reducing daily sugar intake by 50% for 12 weeks?
* How does sweet intensity change after completing dietary modification for 8 weeks?
* Does individual daily sugar intake change after completing dietary modification for 8 weeks?

Researchers will compare reducing daily sugar intake by 50% for 12 weeks to an unmodified diet to see if sugar reduction can change sweet intensity.

Participants will:

* Reduce daily sugar intake by 50% or maintain an unmodified diet for 12 weeks.
* Visit the clinic three times for anthropometric measurements, sweet perception tests, and to complete questionnaires.
* Keep a diet record for a total of 15 days during the research period.


Eligibility Criteria:
Inclusion Criteria:

* People with a fasting blood sugar level below 126 mg/dL or an HbA1C below 6.5% in the past 6 months, who are not currently being treated for diabetes.
* People who score 10 or more points on the sweet food consumption behavior questionnaire.
* People who are able to communicate in the Thai language.
* People who are able to chat and use video calls via the Line application.
* People who agree to modify their diet and beverages according to the recommendations of a dietitian.
* People who agree to undergo sweet taste testing, complete a food record, and fill out a questionnaire.

Exclusion Criteria:

* People with uncontrolled chronic conditions who have had changes in their treatment within the past 3 months.
* People with a history of severe illness in the past 6 months.
* People who regularly use medication, excluding contraceptives and vitamins.
* Pregnant women.
* People who have experienced a weight change of at least 10% over the past 3 months.
Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Purpose: The aim of this clinical trail is to evaluate Tetrathiomolybdate (TM) in the treatment of hormone refractory prostate cancer.

Tetrathiomolybdate or TM, a drug developed for Wilson's Disease, removes copper from the bloodstream. Copper is a key factor in angiogenesis (blood vessel growth)- a process that occurs normally in the body but becomes uncontrolled in cancerous cells. Tetrathiomolybdate essentially wages war against copper, which serves to choke off tumor growth. Realizing the key role of copper in angiogenesis, researchers have begun exploring treatment with Tetrathiomolybdate for different types of cancers. This clinical trial will evaluate the effectiveness of Tetrathiomolybdate in the treatment of patients with hormone refractory prostate cancer. Hormone refractory prostate cancer refers to advanced disease in which the patient no longer responding to conventional hormonal treatment.

Eligibility Criteria:
Inclusion:

* Patients must have histologic diagnosis of adenocarcinoma of the prostate with progression following hormonal therapy and antiandrogen withdrawal.
* Patients must have minimal disease (defined as bone metastasis or visceral disease with no impairment of organ function or pain severe enough to require narcotics for control).
* Adequate bone marrow and renal function
* ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 (a measure of general well being where 1 represents asymptomatic and 5 represents death)
* Life expectancy of at least 16 weeks
* Must have completed radiation more than 4 weeks prior to registration and must have a rising PSA (Prostate Specific Antigen) and lesion outside of the radiation field

Exclusion:

* Patients with an elevated PSA as the only evidence of disease
* Clinical evidence of spinal cord compression
* History of prior malignancy within the past 5 years (with the exception of in situ carcinoma of any site or nonmelanoma skin cancer)